e-mail Print Share

Dental Products

Overview

To help clarify and provide context on oral health issues and dental products, the ADA provides scientific evidence, information and commentary to a wide variety of audiences including the dental profession, media, government agencies and the public. The links below provide access to Association's communications on a number dental product issues.

Click on this link to learn about recent oral health safety alerts.

Letters & Testimony

  • October 15, 2012Coalition letter (PDF) advising the Food and Drug Administration (FDA) on the public health impact of rescheduling hydrocodone-containing combination drug products (HCCs) from Schedule III (C-III) to Schedule II (C-II).
  • July 3, 2012Coalition letter (PDF) to the Food and Drug Administration on the clinical development and use of sedation products in adult and pediatric age groups.
  • June 15, 2012Coalition letter (PDF) urging the House conference committee to retain, amend or strip several drug shortage provisions in H.R. 5651, the Food and Drug Administration Reform Act of 2012.
  • June 15, 2012Coalition letter (PDF) urging the Senate conference committee to retain, amend or strip several drug shortage provisions in S. 3187, the Food and Drug Administration Safety and Innovation Act.
  • May 1, 2012Coalition letter (PDF) urging the House Committee on Energy and Commerce to make several changes to the drug shortage provisions contained in the discussion draft of H.R. 5651, the Food and Drug Administration Safety and Innovation Act.
  • April 23, 2012Coalition letter (PDF) expressing support for the drug shortage provisions in the discussion draft of S. 3187, the Food and Drug Administration Safety and Innovation Act.

ADA Resources

Additional Resources

Contact Us

Washington Office
1111 14th Street NW, Suite 1100
Washington, DC 20005
202.898.2400
Email: govtpol@ada.org

 

State Government Affairs
211 East Chicago Avenue
Chicago, IL 60611
312.440.2525
Email: govtpol@ada.org